You are here

Irinotecan Study For Cervical Cancer

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kaoshiung, , 813 Taiwan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Uterine Cervical Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically documented, advanced or recurrent squamous cell carcinoma of uterine
cervix. Patients may have received concurrent (with radiotherapy) or (neo)adjuvant
(before or after local treatment) chemotherapy for primary tumor providing that at
least 6 months have passed from the completion of previous therapy and the diagnosis
of recurrent disease was documented

- Having measurable lesion(s), without previous radiation therapy.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients had ever received primary chemotherapy for cervical cancer other than
mentioned previously (in the inclusion criteria).

- Patients ever received cisplatin with total dose > 300 mg/m2 and received radiotherapy
or local treatment delivered to the target lesion.

NCT00136955
Pfizer
Completed
Irinotecan Study For Cervical Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now